Medicines contracts with accession option
Original notice title
Germany – Pharmaceutical products – Arzneimittelverträge mit Beitrittsoption
Opportunity Score
Why this score?
Opportunity
30 / 100
Complexity
40 / 100
Risk factors
The notice explicitly states it is not a public procurement under EU directives. This may limit transparency, legal rec...
No estimated value or budget is provided. Bidders cannot assess the potential volume or revenue, making bid/no-bid deci...
No procurement documents available
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 3 lots
- Duration until Dec 2027
- Supply of pharmaceutical products under framework agreements with accession option (Beitrittsoption).
- 7 lots covering active substances: Apremilast, Certolizumab pegol, Dolutegravir, Eltrombopag (excluding SAA), Eltrombopag (Revolade®), Guanfacin, Mesalazin.
Show full summary
This is a framework agreement with an accession option (Beitrittsoption) for the supply of pharmaceutical products, issued by BARMER Beschaffung und Vergabe (a German health insurance entity). The notice explicitly states that it is not a public procurement under Directive 2014/24/EU. There are 7 lots covering different active substances. The award is 100% based on price. No estimated value is provided. The deadline for submission is November 1, 2027, offering a very long submission period. The language of the procedure is German only. No procurement documents were analyzed beyond the notice, and key details such as eligibility criteria and required documents are missing.
Risks
The notice explicitly states it is not a public procurement under EU directives. This may limit transparency, legal rec...
No estimated value or budget is provided. Bidders cannot assess the potential volume or revenue, making bid/no-bid deci...
No procurement documents available
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- No variants allowed.
Administrative
- Submission via electronic platform only: Open portal
- Language of the procedure: German.
Requirements may be incomplete.
Award Criteria
Lot 1
Lot 2
Lot 3
Lot 4
Lot 5
Lot 6
Lot 7
Buyer
Location
Wuppertal, DEU
Website
Identifier
992-80322-57
Activity
Health
Lots (7)
LOT-0001
Apremilast
Pharmaceutical products containing the active substance Apremilast.
Location
Duration
Category
Award Criteria
Deadline
Award details
Preis
Show original TED data
Original TED description
Vertragsgegenständlich sind Arzneimittel, die den/die im Titel genannte(n) Wirkstoff/Wirkstoffkombination enthalten.
LOT-0002
Certolizumab pegol
Pharmaceutical products containing the active substance Certolizumab pegol.
Location
Duration
Category
Award Criteria
Deadline
Award details
Preis
Show original TED data
Original TED description
Vertragsgegenständlich sind Arzneimittel, die den/die im Titel genannte(n) Wirkstoff/Wirkstoffkombination enthalten.
LOT-0003
Dolutegravir
Pharmaceutical products containing the active substance Dolutegravir.
Location
Duration
Category
Award Criteria
Deadline
Award details
Preis
Show original TED data
Original TED description
Vertragsgegenständlich sind Arzneimittel, die den/die im Titel genannte(n) Wirkstoff/Wirkstoffkombination enthalten.
LOT-0004
Eltrombopag (ausgenommen SAA)
Vertragsgegenständlich sind Arzneimittel, die den/die im Titel genannte(n) Wirkstoff/Wirkstoffkombination enthalten.
Location
Duration
Category
Award Criteria
Award details
Preis
LOT-0005
Eltrombopag (Revolade®)
Vertragsgegenständlich sind Arzneimittel, die den/die im Titel genannte(n) Wirkstoff/Wirkstoffkombination enthalten.
Location
Duration
Category
Award Criteria
Award details
Preis
LOT-0006
Guanfacin
Vertragsgegenständlich sind Arzneimittel, die den/die im Titel genannte(n) Wirkstoff/Wirkstoffkombination enthalten.
Location
Duration
Category
Award Criteria
Award details
Preis
LOT-0007
Mesalazin (oral, ohne retard in 0,5 g, 1,0 g, 2,0 g, 4,0 g + TMR_500 mg)
Vertragsgegenständlich sind Arzneimittel, die den/die im Titel genannte(n) Wirkstoff/Wirkstoffkombination enthalten.
Location
Duration
Category
Award Criteria
Award details
Preis
Procurement Details
- Publication date
- 18 Dec 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 848382-2025
Documents (1)
Similar tenders
Germany – Site preparation work – VE111 Baustelleneinrichtung (119VM514 / Kronsh,SanDstBw,Ersatzneub. ZInstSanBw)
Poland – Advertising and marketing services – Zaplanowanie i realizacja kampanii Ministerstwa Finansów z zakresu działalności resortu finansów
France – Insurance services – Prestations de services d'assurance pour groupement le groupement hospitalier de territoire Yvelines Nord
Finland – Architectural, construction, engineering and inspection services – Tietomallikoordinaattori-, inventointimittaus- ja mallinnuspalvelujen puitejärjestely 2026-2028 (2028-2030)
Greece – Cultural event organisation services – ΛΕΙΤΟΥΡΓΙΑ ΤΟΥ ΘΕΑΤΡΟΥ ΟΛΥΜΠΙΑ ΜΑΡΙΑ ΚΑΛΛΑΣ ΜΕ ΕΞΕΙΔΙΚΕΥΜΕΝΟ ΠΡΟΣΩΠΙΚΟ
Spain – Architectural, construction, engineering and inspection services – Redacción del Proyecto Básico y de Ejecución, Redacción del Estudio de Seguridad y Salud y Dirección de Obra para la construcción del I.E.S. Nº 1 de 12+0 uds. (Fase 1) en la urbanización El Bosque de Pioz (Guadalajara).
Opportunity Score
Why this score?
Opportunity
30 / 100
Complexity
40 / 100
Risk factors
The notice explicitly states it is not a public procurement under EU directives. This may limit transparency, legal rec...
No estimated value or budget is provided. Bidders cannot assess the potential volume or revenue, making bid/no-bid deci...
No procurement documents available
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications